<DOC>
	<DOC>NCT00004667</DOC>
	<brief_summary>OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II. Assess the safety of von Willebrand factor in these patients.</brief_summary>
	<brief_title>Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients receive 1 dose of von Willebrand factor concentrate. Timed blood studies are performed for the next 96 hours. Patients are followed every 2 weeks for 16 weeks, and at 24, 36, and 52 weeks.</detailed_description>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: von Willebrand's disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>hematologic disorders</keyword>
	<keyword>rare disease</keyword>
	<keyword>von Willebrand's disease</keyword>
</DOC>